{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T10:32:12Z","timestamp":1761129132306},"reference-count":20,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2014,5,1]],"date-time":"2014-05-01T00:00:00Z","timestamp":1398902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagnostic Microbiology and Infectious Disease"],"published-print":{"date-parts":[[2014,5]]},"DOI":"10.1016\/j.diagmicrobio.2014.01.017","type":"journal-article","created":{"date-parts":[[2014,1,31]],"date-time":"2014-01-31T22:34:53Z","timestamp":1391207693000},"page":"54-59","source":"Crossref","is-referenced-by-count":14,"title":["In vitro activity of tigecycline against isolates collected from complicated skin and skin structure infections and intra-abdominal infections in Africa and Middle East countries: TEST 2007\u20132012"],"prefix":"10.1016","volume":"79","author":[{"given":"M.I.","family":"Renteria","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.J.","family":"Biedenbach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.K.","family":"Bouchillon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.J.","family":"Hoban","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Raghubir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Sajben","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Mokaddas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.diagmicrobio.2014.01.017_bb0005","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1586\/eri.11.107","article-title":"Will new antimicrobials overcome resistance among Gram-negatives?","volume":"9","author":"Bassetti","year":"2011","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"1","key":"10.1016\/j.diagmicrobio.2014.01.017_bb0010","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.clinthera.2011.11.023","volume":"34","author":"Bertrand","year":"2012","journal-title":"Clinical Therapeutics"},{"issue":"6","key":"10.1016\/j.diagmicrobio.2014.01.017_bb0015","doi-asserted-by":"crossref","first-page":"851","DOI":"10.2217\/thy.09.74","article-title":"Tigecycline: an overview and update","volume":"6","author":"Blondeau","year":"2009","journal-title":"Therapy"},{"issue":"6","key":"10.1016\/j.diagmicrobio.2014.01.017_bb0020","doi-asserted-by":"crossref","first-page":"17","DOI":"10.2165\/11599800-000000000-00000","article-title":"Essentials for selecting antimicrobial therapy for intra-abdominal infections","volume":"72","author":"Blot","year":"2012","journal-title":"Drugs"},{"issue":"2","key":"10.1016\/j.diagmicrobio.2014.01.017_bb0025","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.ijantimicag.2008.07.031","article-title":"Comparative in vitro activity of tigecycline and other antimicrobials against Gram-negative and Gram-positive organisms collected from the Asia-Pacific Rim as part of the Tigecycline Evaluation and Surveillance Trial (TEST)","volume":"33","author":"Bouchillon","year":"2009","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.diagmicrobio.2014.01.017_bb0030","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1097\/QCO.0b013e3283553441","article-title":"Methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci, and other Gram-positives in healthcare","volume":"25","author":"Calfee","year":"2012","journal-title":"Curr Opin Infect Dis."},{"key":"10.1016\/j.diagmicrobio.2014.01.017_bb0035","series-title":"Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard-Ninth Edition, in Document M07-A9","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2012"},{"key":"10.1016\/j.diagmicrobio.2014.01.017_bb0040","series-title":"CLSI document M100-S22","article-title":"Performance Standards for Antimicrobial Susceptibility Testing; Twenty-first Informational Supplement","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2012"},{"key":"10.1016\/j.diagmicrobio.2014.01.017_bb0045","first-page":"181","article-title":"Tigecycline: an evidence-based review of its antibacterial activity and effectiveness in complicated skin and soft tissue and intraabdominal infections","volume":"1","author":"Dunn","year":"2006","journal-title":"Core Evid"},{"key":"10.1016\/j.diagmicrobio.2014.01.017_bb0050","author":"Food and Drug Administration (FDA)"},{"key":"10.1016\/j.diagmicrobio.2014.01.017_bb0055","doi-asserted-by":"crossref","first-page":"309","DOI":"10.2147\/tcrm.2007.3.2.309","article-title":"Skin and skin structure infections: treatment with newer generation fluoroquinolones","volume":"3","author":"Giordano","year":"2007","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.diagmicrobio.2014.01.017_bb0060","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.ijantimicag.2011.12.012","article-title":"Fourteen years in resistance","volume":"4","author":"Livermore","year":"2012","journal-title":"Int J Antimicrob Agents"},{"issue":"2","key":"10.1016\/j.diagmicrobio.2014.01.017_bb0065","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.diagmicrobio.2012.05.032","article-title":"In vitro activity of tigecycline and comparators against organisms associated with intra-abdominal infections collected as part of TEST (2004\u20132009)","volume":"74","author":"Mayne","year":"2012","journal-title":"Diagn Microbiol Infect Di"},{"key":"10.1016\/j.diagmicrobio.2014.01.017_bb0070","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s11739-012-0828-3","article-title":"Antimicrobial resistance in internal medicine wards","volume":"3","author":"Menichetti","year":"2012","journal-title":"Intern Emerg Me, Suppl"},{"issue":"5","key":"10.1016\/j.diagmicrobio.2014.01.017_bb0075","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1517\/14656561003596350","article-title":"Treatment of Acinetobacter infections","volume":"11","author":"Michalopoulos","year":"2010","journal-title":"Expert Opin Pharmacother"},{"issue":"1","key":"10.1016\/j.diagmicrobio.2014.01.017_bb0080","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ijid.2011.09.021","article-title":"Activity of tigecycline and comparators against skin and skin structure pathogens: global results of the tigecycline evaluation and surveillance trial, 2004\u20132009","volume":"16","author":"Namdari","year":"2012","journal-title":"Int J Infect Dis"},{"issue":"3","key":"10.1016\/j.diagmicrobio.2014.01.017_bb0085","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.jhin.2011.04.028","article-title":"Community-associated methicillin-resistant Staphylococcus aureus strains as a cause of healthcare-associated infection","volume":"79","author":"Otter","year":"2011","journal-title":"J Hosp Infect"},{"issue":"8","key":"10.1016\/j.diagmicrobio.2014.01.017_bb0090","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1592\/phco.26.8.1099","article-title":"Tigecycline: first of a new class of antimicrobial agents","volume":"26","author":"Rose","year":"2006","journal-title":"Pharmacotherapy"},{"issue":"6","key":"10.1016\/j.diagmicrobio.2014.01.017_bb0095","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.ijantimicag.2007.07.020","article-title":"Use of in vitro susceptibility and pathogen prevalence data to model the expected clinical success rates of tigecycline and other commonly used antimicrobials for empirical treatment of complicated skin and skin structure infections","volume":"30","author":"Sader","year":"2007","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.diagmicrobio.2014.01.017_bb0100","series-title":"Federal Drug Administration (FDA) product information","author":"Tygacil\u00ae","year":"2010"}],"container-title":["Diagnostic Microbiology and Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889314000509?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889314000509?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,7]],"date-time":"2018-10-07T00:56:41Z","timestamp":1538873801000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0732889314000509"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,5]]}},"alternative-id":["S0732889314000509"],"URL":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2014.01.017","relation":{},"ISSN":["0732-8893"],"issn-type":[{"value":"0732-8893","type":"print"}],"subject":[],"published":{"date-parts":[[2014,5]]}}}